4.7 Review

An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis

期刊

JOURNAL OF CLINICAL MEDICINE
卷 11, 期 9, 页码 -

出版社

MDPI
DOI: 10.3390/jcm11092302

关键词

5-aminosalicylic acid; azathioprine; biologic therapy; corticosteroids; inflammatory bowel disease; small molecule; tofacitinib; ulcerative colitis

资金

  1. Janssen-Cilag
  2. Roche
  3. Pfizer

向作者/读者索取更多资源

The main goals of ulcerative colitis (UC) treatment are to induce and maintain disease remission, reduce complications, and improve quality of life. Although a cure has not been found, new therapeutic strategies are emerging, while non-biological drugs remain a mainstay of treatment.
The main goals of Ulcerative Colitis (UC) treatment are to both induce and maintain the clinical and endoscopic remission of disease, reduce the incidence of complications such as dysplasia and colorectal carcinoma and improve quality of life. Although a curative medical treatment for UC has not yet been found, new therapeutic strategies addressing specific pathogenetic mechanisms of disease are emerging. Notwithstanding these novel therapies, non-biological conventional drugs remain a mainstay of treatment. The aim of this review is to summarize current therapeutic strategies used as treatment for ulcerative colitis and to briefly focus on emerging therapeutic strategies, including novel biologic therapies and small molecules. To date, multiple therapeutic approaches can be adopted in UC and the range of available compounds is constantly increasing. In this era, the realization of well-designed comparative clinical trials, as well as the definition of specific therapeutic models, would be strongly suggested in order to achieve personalized management for UC patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据